Alpha Tau Medical (DRTS) Income from Discontinued Operations (2025 - 2026)

Alpha Tau Medical (DRTS) posted quarterly Income from Discontinued Operations of 11000.0 for Q1 2026, down 111.11% year-on-year from 99000.0 in Q1 2025, and down 111.11% on a QoQ basis from 99000.0 in Q1 2025.

Alpha Tau Medical (DRTS) Income from Discontinued Operations (2025 - 2026) Analysis & Trends

Alpha Tau Medical (DRTS) has reported Income from Discontinued Operations for 2 consecutive years, with 11000.0 the latest figure, recorded in Q1 2026.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Income (Discontinued) (Qtr)
1 Oculis Holding AG 66,140.12 Bn 66,139.83 Bn - -
2 Nanobiotix 1,912.79 Bn 1,912.73 Bn - -
3 Akari Therapeutics 1,022.34 Bn 1,022.34 Bn - -
4 BeOne Medicines 472.60 Bn 467.81 Bn 1.35 Bn -
5 Vertex Pharmaceuticals 122.34 Bn 115.09 Bn 2.59 Bn -
6 Regeneron Pharmaceuticals 70.14 Bn 61.39 Bn 3.31 Bn -
7 Belite Bio 62.79 Bn 62.79 Bn - -
8 Argenx Se 56.19 Bn 51.00 Bn 1.41 Bn -
9 Alnylam Pharmaceuticals 37.50 Bn 34.49 Bn 959.66 Mn -
10 Alpha Tau Medical 1.11 Bn 1.11 Bn - -11,000.00

Historic Data

Download Data
DateValue
Mar 31, 2026 -11,000.00
Mar 31, 2025 99,000.00